多黏菌素治疗患者肾毒性与神经毒性发生率的系统综述
该系统综述检索了Medline、Embase和Cochrane Library数据库(截至2020年1月2日),纳入237篇报告,分析多黏菌素治疗患者的肾毒性与神经毒性发生率。多黏菌素组总体肾毒性率为0.282(95%CI 0.259-0.307),排除吸入为主或评估方法不合国际标准的研究后为0.391(95%CI 0.364-0.419);与非多黏菌素方案相比肾毒性风险更高(OR 2.23,95%CI 1.58-3.15,p<0.001)。总体神经毒性率为0.030(95%CI 0.020-0.043),与非多黏菌素方案相比无显著差异(p 0.051)。
要点
- 多黏菌素治疗总体肾毒性率0.282,严格评估标准下为0.391。
- 多黏菌素肾毒性风险高于非多黏菌素方案(OR 2.23)。
- 总体神经毒性率0.030,与非多黏菌素方案无显著差异。
核心结论
- 多黏菌素治疗与非多黏菌素方案相比肾毒性风险更高,神经毒性发生率总体较低且组间无显著差异。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase和Cochrane Library数据库(2020年1月2日),纳入237篇随机对照试验、队列和病例对照研究,多数为单臂观察性研究。
- 肾毒性分析纳入35,569例接受多黏菌素治疗的患者,采用随机效应模型进行荟萃分析,数据允许时用混合效应模型作亚组分析。
主要发现
- 多黏菌素治疗患者总体肾毒性率为0.282(95%CI 0.259-0.307)。
- 排除吸入为主或肾毒性评估未采用RIFLE、KDIGO或AKIN标准的研究后,肾毒性率为0.391(95%CI 0.364-0.419)。
- 与非多黏菌素方案相比,多黏菌素肾毒性比值比为2.23(95%CI 1.58-3.15),p<0.001。
- 多黏菌素类型、剂量、患者年龄、合并肾毒性药物数量及利尿剂、糖肽类或血管加压药使用对肾毒性率有显著影响。
- 多黏菌素治疗总体神经毒性率为0.030(95%CI 0.020-0.043),与非多黏菌素方案相比差异无统计学意义(p 0.051)。
关键数值与推荐
- 肾毒性评估采用国际公认标准RIFLE、KDIGO或AKIN。
- 肾毒性合并率0.282(95%CI 0.259-0.307);严格标准下0.391(95%CI 0.364-0.419)。
- 多黏菌素vs非多黏菌素肾毒性OR 2.23(95%CI 1.58-3.15),p<0.001。
- 神经毒性合并率0.030(95%CI 0.020-0.043),组间比较p 0.051。
临床怎么用
- 使用多黏菌素时应重视肾毒性监测,尤其对高龄、合并多种肾毒性药物或使用利尿剂、糖肽类、血管加压药的患者。
- 神经毒性风险总体较低,但仍需在治疗期间保持临床观察。
局限性
- 纳入研究多数为单臂观察性研究,可能存在异质性与偏倚。
- 肾毒性率受吸入用药比例和评估标准不统一影响,排除相关研究后发生率明显升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nephrotoxicity and neurotoxicity are commonly associated with polymyxin treatment; however, the emergence of multidrug-resistant Gram-negative bacteria with limited therapeutic options has resulted in increased use of polymyxins. OBJECTIVES: To determine the rates of nephrotoxicity and neurotoxicity during polymyxin treatment and whether any factors influence these. DATA SOURCES: Medline, Embase and Cochrane Library databases were searched on 2 January 2020. STUDY ELIGIBILITY CRITERIA: Studies reporting nephrotoxicity and/or neurotoxicity rates in patients with infections treated with polymyxins were included. Reviews, meta-analyses and reports not in English were excluded. PARTICIPANTS: Patients hospitalized with infections treated with systemic or inhaled polymyxins were included. For comparative analyses, patients treated with non-polymyxin-based regimens were also included. METHODS: Meta-analyses were performed using a random-effects model; subgroup meta-analyses were conducted where data permitted using a mixed-effects model. RESULTS: In total, 237 reports of randomized controlled trials, cohort and case-control studies were eligible for inclusion; most were single-arm observational studies. Nephrotoxic events in 35,569 patients receiving polymyxins were analysed. Overall nephrotoxicity rate was 0.282 (95% confidence interval (CI) 0.259-0.307). When excluding studies where >50% of patients received inhaled-only polymyxin treatment or nephrotoxicity assessment was by methods other than internationally recognized criteria (RIFLE, KDIGO or AKIN), the nephrotoxicity rate was 0.391 (95% CI 0.364-0.419). The odds of nephrotoxicity were greater with polymyxin therapies compared to non-polymyxin-based regimens (odds ratio 2.23 (95% CI 1.58-3.15); p < 0.001). Meta-analyses showed a significant effect of polymyxin type, dose, patient age, number of concomitant nephrotoxins and use of diuretics, glycopeptides or vasopressors on the rate of nephrotoxicity. Polymyxin therapies were not associated with a significantly different rate of neurotoxicity than non-polymyxin-based regimens (p 0.051). The overall rate of neurotoxicity during polymyxin therapy was 0.030 (95% CI 0.020-0.043). CONCLUSIONS: Polymyxins are associated with a higher risk of nephrotoxicity than non-polymyxin-based regimens.
引用
- Wagenlehner F, Lucenteforte E, Pea F, et al. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect. 2021. PMID: 33359542. doi:10.1016/j.cmi.2020.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。